OCZ103-OS

Oncozyme Pharma Inc. · Phase 2 active Small molecule

At a glance

Generic name	OCZ103-OS
Also known as	pentamidine bis(2-hydroxyethanesulfonate
Sponsor	Oncozyme Pharma Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (PHASE2)
An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OCZ103-OS CI brief — competitive landscape report
OCZ103-OS updates RSS · CI watch RSS
Oncozyme Pharma Inc. portfolio CI